Amgen Share Price Today
(NASDAQ: AMGN)

Name: Amgen Share Price Today (NASDAQ: AMGN) - Amgen Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Amgen share price is $306.95 & ₹26,229.18 as on 29 Mar 2025, 2.30 'hrs' IST

$306.95

▲

1.18

(0.39%)

Market is closed - opens 7 PM, 31 Mar 2025

View live Amgen share price in Dollar and Rupees. Guide to invest in Amgen stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Amgen, along with analyst recommendations, forecasts, and comprehensive financials.

Amgen share price movements

Today's Low: $304.72
Today's High: $308.15
$306.95
0.73%
Downside
Day's Volatility :1.11%
Upside
0.39%
52 Weeks Low: $253.30
52 Weeks High: $346.85
$306.95
17.48%
Downside
52 Weeks Volatility :26.97%
Upside
11.5%

Amgen (AMGN) Returns

Period	Amgen Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	18.38%	4.0%	-12.2%
6 Months	-4.74%	-5.6%	-4.4%
1 Year	8.45%	-2.2%	5.8%
3 Years	26.93%	4.7%	18.5%

Amgen (AMGN) Key Statistics

in dollars & INR

Previous Close	$305.77
Open	$307.44
Today's High	$308.15
Today's Low	$304.715
Market Capitalization	$164.9B
Today's Volume	$1.8M
52 Week High	$346.85
52 Week Low	$253.3
Revenue TTM	$33.4B
EBITDA	$15.2B
Earnings Per Share (EPS)	$7.55
PE Ratio	40.66
Dividend Yield	3.11%
Profit Margin	12.24%
Quarterly Earnings Growth YOY	-0.19%
Return On Equity TTM	67.55%

How to invest in Amgen Stock (AMGN) from India?

It is very easy for Indian residents to invest directly in Amgen from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Amgen stock in both Indian Rupees (INR) and US Dollars (USD). Search for Amgen or AMGN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Amgen or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Amgen shares which would translate to 0.003 fractional shares of Amgen as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Amgen, in just a few clicks!

Returns in Amgen (AMGN) for Indian investors in Rupees

The Amgen stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Amgen investment value today

Current value as on today

₹1,10,985

Returns

₹10,985

(+10.99%)

Returns from Amgen Stock

₹8,448 (+8.45%)

Dollar Returns

₹2,538 (+2.54%)

Indian investors sentiment towards Amgen (AMGN)

-28.79%

Period: Feb 27, 2025 to Mar 29, 2025. Change in 30 Days versus previous period

Investment in Amgen Shares from India has dropped by -28.79% over the past 30 days, indicating reduced transactional activity.

-48%

Period: Feb 27, 2025 to Mar 29, 2025. Change in 30 Days versus previous period

Search interest for Amgen Stock from India on INDmoney has decreased by -48% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Amgen Stock (AMGN Ticker)

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	6956	726.83	1.06%
Motilal Oswal S&P 500 Index Fund Direct Growth	4637	137.35	0.33%
ICICI Prudential US Bluechip Equity Fund Direct Plan Growth	17000	2506.65	1.41%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	799	0.00	1.42%

Global Institutional Holdings in Amgen

Vanguard Group Inc
9.81%
BlackRock Inc
8.50%
State Street Corp
5.48%
Morgan Stanley - Brokerage Accounts
2.71%
Charles Schwab Investment Management Inc
2.46%
PRIMECAP Management Company
2.42%

Analyst Recommendation on Amgen

Buy

56%Buy

35%Hold

8%Sell

Based on 37 Wall street analysts offering stock ratings for Amgen(by analysts ranked 0 to 5 stars)

Based on 37 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Amgen Stock (AMGN)

What analysts predicted

Upside of 2.93%

Target:

$315.95

Current:

$306.95

Insights on Amgen Stock (Ticker Symbol: AMGN)

Price Movement
In the last 3 months, AMGN stock has moved up by 16.9%
Increasing Revenue
Amgen Inc. has shown consistent revenue growth over the last four quarters. The company's revenue increased from $7.44 billion to $9.08 billion, reflecting an average increase of 6.3% each quarter.
Decreasing Net Profit
Amgen Inc. has seen a significant decline in its net profit over the last two quarters. It decreased from $2.83 billion to $627 million, reflecting an average drop of 77.8% per quarter.
AMGN vs ABBV (1 yr)
In the last 1 year, Abbvie Inc has given 12.7% return, outperforming this stock by 4.7%
Price to Sales
Amgen Inc. has a Price-to-Sales Ratio of 4.9, meaning that investors are willing to pay $4.9 for every $1 of sales the company generates. In comparison, Abbvie Inc. has a higher Price-to-Sales Ratio of 6.4, indicating that investors are willing to pay more for each dollar of sales for Abbvie.

AMGN Amgen Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$23.4B	↓ 1.62%
Net Income	$7.8B	↓ 6.58%
Net Profit Margin	33.57%	↓ 1.78%

	FY20	Y/Y Change
Revenue	$25.4B	↑ 8.83%
Net Income	$7.3B	↓ 7.37%
Net Profit Margin	28.57%	↓ 5.0%

	FY21	Y/Y Change
Revenue	$26.0B	↑ 2.18%
Net Income	$5.9B	↓ 18.87%
Net Profit Margin	22.68%	↓ 5.89%

	FY22	Y/Y Change
Revenue	$26.3B	↑ 1.32%
Net Income	$6.6B	↑ 11.18%
Net Profit Margin	24.89%	↑ 2.21%

	FY23	Y/Y Change
Revenue	$28.2B	↑ 7.09%
Net Income	$6.7B	↑ 2.52%
Net Profit Margin	23.83%	↓ 1.06%

	FY24	Y/Y Change
Revenue	$33.4B	↑ 18.57%
Net Income	$4.1B	↓ 39.11%
Net Profit Margin	12.24%	↓ 11.59%

	Q3 FY23	Q/Q Change
Revenue	$6.9B	↓ 1.19%
Net Income	$1.7B	↑ 25.45%
Net Profit Margin	25.06%	↑ 5.32%

	Q4 FY23	Q/Q Change
Revenue	$8.2B	↑ 18.73%
Net Income	$767.0M	↓ 55.66%
Net Profit Margin	9.36%	↓ 15.7%

	Q1 FY24	Q/Q Change
Revenue	$7.4B	↓ 9.14%
Net Income	$-113.0M	↓ 114.73%
Net Profit Margin	-1.52%	↓ 10.88%

	Q2 FY24	Q/Q Change
Revenue	$8.4B	↑ 12.64%
Net Income	$746.0M	↓ 760.18%
Net Profit Margin	8.89%	↑ 10.41%

	Q3 FY24	Q/Q Change
Revenue	$8.5B	↑ 1.37%
Net Income	$2.8B	↑ 279.36%
Net Profit Margin	33.28%	↑ 24.39%

	Q4 FY24	Q/Q Change
Revenue	$9.1B	↑ 6.86%
Net Income	$627.0M	↓ 77.84%
Net Profit Margin	6.9%	↓ 26.38%

	FY19	Y/Y Change
Profit	$19.0B	↓ 3.26%

	FY20	Y/Y Change
Profit	$19.3B	↑ 1.36%

	FY21	Y/Y Change
Profit	$19.5B	↑ 1.35%

	FY22	Y/Y Change
Profit	$19.9B	↑ 2.01%

	FY23	Y/Y Change
Profit	$19.7B	↓ 0.89%

	FY24	Y/Y Change
Profit	$20.6B	↑ 4.19%

	Q3 FY23	Q/Q Change
Profit	$5.1B	↓ 1.47%

	Q4 FY23	Q/Q Change
Profit	$5.1B	↓ 0.26%

	Q1 FY24	Q/Q Change
Profit	$4.2B	↓ 16.46%

	Q2 FY24	Q/Q Change
Profit	$5.2B	↑ 21.31%

	Q3 FY24	Q/Q Change
Profit	$5.2B	↑ 0.8%

	Q4 FY24	Q/Q Change
Profit	$6.0B	↑ 15.04%

	FY19	Y/Y Change
Operating Cash Flow	$9.2B	↓ 19.0%
Investing Cash Flow	$5.7B	↓ 60.19%
Financing Cash Flow	$-15.8B	↓ 29.89%

	FY20	Y/Y Change
Operating Cash Flow	$10.5B	↑ 14.72%
Investing Cash Flow	$-5.4B	↓ 194.61%
Financing Cash Flow	$-4.9B	↓ 69.13%

	FY21	Y/Y Change
Operating Cash Flow	$9.3B	↓ 11.77%
Investing Cash Flow	$733.0M	↓ 113.57%
Financing Cash Flow	$-8.3B	↑ 69.94%

	FY22	Y/Y Change
Operating Cash Flow	$9.7B	↑ 4.97%
Investing Cash Flow	$-6.0B	↓ 924.56%
Financing Cash Flow	$-4.0B	↓ 51.19%

	FY23	Y/Y Change
Operating Cash Flow	$8.5B	↓ 12.86%
Investing Cash Flow	$-26.2B	↑ 333.55%
Financing Cash Flow	$21.0B	↓ 621.38%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$2.8B	↓ 32.83%
Investing Cash Flow	$-262.0M	↑ 24.17%
Financing Cash Flow	$-2.0B	↑ 65.7%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$538.0M	↓ 80.51%
Investing Cash Flow	$-27.1B	↑ 10239.31%
Financing Cash Flow	$2.8B	↓ 237.36%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$689.0M	↑ 28.07%
Investing Cash Flow	$-217.0M	↓ 99.2%
Financing Cash Flow	$-1.7B	↓ 162.02%

Amgen Technicals Summary

Sell

Neutral

Buy

Amgen is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Amgen (AMGN) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Amgen Inc.	-0.36%	-4.74%	8.45%	26.93%	51.41%
Eli Lilly And Company	-10.66%	-7.16%	8.15%	187.22%	492.93%
Johnson & Johnson	-0.79%	1.02%	3.76%	-7.63%	24.85%
Merck & Co. Inc.	-3.27%	-21.42%	-31.88%	8.75%	15.97%
Novo Nordisk A/s	-23.55%	-41.8%	-45.67%	24.81%	130.23%
Abbvie Inc	-1.79%	3.95%	13.57%	26.64%	169.44%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Amgen Inc.	40.66	40.66	1.04	20.64	0.68	0.06	0.03	10.95
Eli Lilly And Company	70.0	70.0	1.21	23.22	0.84	0.15	0.01	15.81
Johnson & Johnson	28.27	28.27	1.11	10.57	0.2	0.08	0.03	29.7
Merck & Co. Inc.	13.24	13.24	0.8	8.98	0.41	0.14	0.04	18.32
Novo Nordisk A/s	21.26	21.26	1.08	0.0	0.81	0.22	0.02	32.31
Abbvie Inc	86.26	86.26	0.43	12.28	0.62	0.08	0.03	1.88

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Amgen Inc.	Buy	$164.9B	51.41%	40.66	12.24%
Eli Lilly And Company	Buy	$738.6B	492.93%	70.0	23.51%
Johnson & Johnson	Buy	$394.5B	24.85%	28.27	15.84%
Merck & Co. Inc.	Buy	$225.4B	15.97%	13.24	26.67%
Novo Nordisk A/s	Buy	$304.6B	130.23%	21.26	34.78%
Abbvie Inc	Buy	$363.2B	169.44%	86.26	7.59%

Amgen Dividend announcements

Amgen Dividends June, 2025
In the quarter ending June,2025. Amgen has declared dividend of $2.38

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Organization	Amgen
Employees	28000
CEO	Mr. Robert A. Bradway
Industry	Health Technology

Management People of Amgen

Name	Title
Mr. Robert A. Bradway	Chairman, CEO & President
Mr. Peter H. Griffith	Executive VP & CFO
Mr. Esteban Santos	Executive Vice President of Operations
Dr. David M. Reese M.D.	Executive VP & CTO
Mr. Murdo Gordon	Executive Vice President of Global Commercial Operations
Mr. Matthew C. Busch	Chief Accounting Officer & VP of Finance
Mr. Scott Skellenger	Senior VP & Chief Information Officer
Dr. Howard Y. Chang M.D., Ph.D.	Senior VP of Global Research & Chief Scientific Officer
Justin G. Claeys	Vice President of Investor Relations
Mr. Jonathan P. Graham J.D.	Executive VP, General Counsel & Secretary

Important FAQs about investing in AMGN Stock from India :

What is Amgen share price today?

Amgen share price today stands at $306.95, Open: $307.44 ; Previous Close: $305.77 ; High: $308.15 ; Low: $304.72 ; 52 Week High: $346.85 ; 52 Week Low: $253.30.

The stock opens at $307.44, after a previous close of $305.77. The stock reached a daily high of $308.15 and a low of $304.72, with a 52-week high of $346.85 and a 52-week low of $253.30.

Can Indians buy Amgen shares?

Yes, Indians can invest in the Amgen (AMGN) from India.

With INDmoney, you can buy Amgen at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Amgen at zero transaction cost.

How can I buy Amgen shares from India?

It is very easy to buy Amgen from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Amgen (AMGN) be purchased?

Yes, you can buy fractional shares of Amgen with INDmoney app.

What are the documents required to start investing in Amgen stocks?

To start investing in Amgen, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.